Summary
Precision oncology has largely been driven by genomic profiling, but success so far has been limited. By combining genomic and proteomic analyses of tumours, proteogenomics holds promise in providing deeper mechanistic insights and generating therapeutic hypotheses to better match patients to targeted treatments than analysing each ‘ome in isolation.
References
Blum, A., Wang, P. & Zenklusen, J. C. SnapShot: TCGA-analyzed tumors. Cell 173, 530 (2018).
Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D. et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J. Clin. Oncol. 38, 3883–3894 (2020).
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).
Mertins, P., Tang, L. C., Krug, K., Clark, D. J., Gritsenko, M. A., Chen, L. et al. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. Nat. Protoc. 13, 1632–1661 (2018).
Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z. et al. Proteogenomic characterization of human colon and rectal cancer. Nature 513, 382–387 (2014).
Wang, J., Mouradov, D., Wang, X., Jorissen, R. N., Chambers, M. C., Zimmerman, L. J. et al. Colorectal cancer cell line proteomes are representative of primary tumors and predict drug sensitivity. Gastroenterology 153, 1082–1095 (2017).
Huang, C., Chen, L., Savage, S. R., Eguez, R. V., Dou, Y., Li, Y. et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell https://doi.org/10.1016/j.ccell.2020.12.007 (2021).
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956–965 (2016).
Wen, B., Li, K., Zhang, Y. & Zhang, B. Cancer neoantigen prioritization through sensitive and reliable proteogenomics analysis. Nat. Commun. 11, 1759 (2020).
Satpathy, S., Jaehnig, E. J., Krug, K., Kim, B. J., Saltzman, A. B., Chan, D. W. et al. Microscaled proteogenomic methods for precision oncology. Nat. Commun. 11, 532 (2020).
Author information
Authors and Affiliations
Contributions
J.T.L. and B.Z. drafted and revised the paper and approved the final version for publication.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent to publish
Not applicable.
Data availability
Not applicable.
Completing interests
The authors declare no competing interests.
Funding information
This work was supported by grants U24 CA210954 from the National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC), by a Cancer Prevention Institute of Texas (CPRIT) award RR160027, and by funding from the McNair Foundation. J.T.L is supported by grant T32 CA203690 from the Translational Breast Cancer Research Training Program. B.Z. is a CPRIT Scholar in Cancer Research and McNair Medical Institute Scholar.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lei, J.T., Zhang, B. Proteogenomics drives therapeutic hypothesis generation for precision oncology. Br J Cancer 125, 1–3 (2021). https://doi.org/10.1038/s41416-021-01346-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-021-01346-5
- Springer Nature Limited
This article is cited by
-
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing
British Journal of Cancer (2022)